TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced the first patient dose in an open‑label, multi‑center...
Simcere Launches Quviviq, New Insomnia Therapy in China
Jiangsu Simcere Pharmaceutical Co., Ltd. (HKG: 2096) announced the nationwide launch of its first prescription...
Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with...
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that it will spin off its...
Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the China National Medical...
Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the National Medical Products Administration (NMPA)...
Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
Boji Medical Technology Co., Ltd. (SHE: 300404) has secured approval from the National Medical Products...
Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) confirmed that China’s National Medical Products...
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has signed an evaluation...
Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
Argo Biopharma, a Shanghai‑based siRNA drug developer, announced a new strategic cooperation agreement with Novartis...
ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs
ChemPartner Pharmatech Co., Ltd. (SHE: 300149) announced that its wholly‑owned subsidiary, Beihai ChemPartner Venture Capital...
AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
American pharmaceutical giant AbbVie (NYSE: ABBV) disclosed that its bispecific T‑cell engager, epcoritamab, has been...
Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
Replicate Bioscience, a pioneer in self‑replicating RNA (srRNA) therapeutics, announced a landmark multi‑year research partnership...
Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug
Simcere Pharmaceutical Group Limited (HKG: 2096) today announced that the National Medical Products Administration (NMPA)...
FDA Unveils RDEP to Accelerate Rare Disease Therapy Development
The U.S. Food and Drug Administration (FDA) today issued the Rare Disease Evidence Principles (RDEP),...
Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC
China’s Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced today that the first patient has...
Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine
Ab&B Bio‑Tech CO., LTD. JS (HKG: 2627) disclosed that its quadrivalent influenza virus subunit vaccine...
Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes
French pharmaceutical giant Sanofi (NASDAQ: SNY) today announced that its investigational drug Tzield (teplizumab) has...
Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest
Zenas BioPharma, Inc. (NASDAQ: ZBIO) and Royalty Pharma, Inc. (NASDAQ: RPRX) announced a milestone partnership...
Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration
Enlaza Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) today announced a multi‑target drug discovery...